MAY 24, 2016 03:32 AM PDT

Nanomedicine Delivers Chemotherapy Drugs to Brain Tumors

WRITTEN BY: Xuan Pham

By packing chemotherapy drugs in nanoscale lipid droplets, researchers say they may have found a new way to treat one of the deadliest forms of primary brain cancer known as glioblastoma multiforme (GBM). Nanotheraputics, as this field of medicine is now called, combines nanotechnology, chemistry, and bioengineering into a remarkable system with seemingly “endless and bright” possibilities, said Ann-Marie Broome, senior author of the newly published study.

 
Image credit: Pixabay.com
 

 Dubbed as the “octopus tumor,” GBMs are characterized with malignant glial cells forming vast networks of tendrils throughout the brain. This makes it nearly impossible to surgically remove all the cancerous tissues. As such, this brain cancer can evade even the most aggressive surgeries, chemotherapies, and radiotherapies, leaving patients with a five-year survival rate of less than 10 percent.
 
Another part of the reason why chemotherapy is ineffective against GBM is the blood-brain barrier (BBB). Designed to protect the brain from the environment, the BBB also prevents drugs from passing through to act on the GBM cancer cells.
 
To breach the BBB, Broome and her team aimed at creating nanocarriers that could ferry drugs into the brain. They designed a micelle – “a bit of fat globule” – that was so small it easily slipped past the BBB. Inside the micelle, the team packaged the chemotherapy drug, temozolomide (TMZ).
 
"Micelles of a certain size will cross the blood-brain barrier carrying a concentrated amount of TMZ," Broome said. To the micelles, they also incorporated platelet-derived growth factors (PDGF), which are proteins that are overexpressed in the cancer cells. "The PDGF is used much like a postal address. The micelle gets it to the street, and the PDGF gets it to the house."
 
Once inside the cancer, the team exploited cancer’s unnatural acidic environment to trigger the release of the drug. "We take advantage of the tumor's natural environment as well as the cellular expression. I'm a big proponent of understanding that microenvironment has an impact on how well you can treat tumors. It's probably why so many therapeutics fail - because you have to take into account the immune system, the local environment, and the cells themselves - all three of these are important considerations."
 
In experiment results, this method worked so well that Broome initially questioned her results. "I was very surprised by how efficiently and well it worked once we got the nanocarrier to those cells," said Broome. But after many validation experiments in different cell lines and using different drug concentrations, the results still proved promising.
 
In the next phase, Broome anticipates more testing with different drugs and other biomarkers for GBM. "[TMZ] may or may not be effective for all types of GBMs. There are subtypes as well as therapeutic-resistant GBMs that these nanocarriers may not impact. We need to continue rigorous testing to verify and validate our initial findings."
 
But for now, the team is excited for the possibilities that have opened up with this nanotherapeutics technology. 
 


Additional source: Medical University Of South Carolina news release

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 24, 2018
Clinical & Molecular DX
APR 24, 2018
An Atlas of the Human Genome
Scientists from the Hebrew University of Jerusalem want to identify individual genes responsible for specific diseases. This goal inspired their new Nature...
APR 27, 2018
Clinical & Molecular DX
APR 27, 2018
Stomach Pain Is A Warning Sign for Meningitis
Simply looking out for the classic warning signs of a meningococcal infection may cause some cases to go unnoticed - at first. A new study from the Institu...
MAY 14, 2018
Clinical & Molecular DX
MAY 14, 2018
Early Differences Between Benign and Malignant Tumors
Physicians are in need of a dependable diagnostic approach for distinguishing between benign and malignant tumors early-on. Once doctors can rule out that ...
MAY 24, 2018
Neuroscience
MAY 24, 2018
Can Brain Fold Patterns Predict Psychosis?
While it's a famous slogan and not meant to be taken verbatim, in neuroscience, it's often true that "Image is everything." A recent stud...
JUN 07, 2018
Genetics & Genomics
JUN 07, 2018
Easily Identifying Pregnancies at Risk for Premature Birth
Premature birth affects almost ten percent of pregnancies and is the leading cause of infant mortality in the US....
JUL 11, 2018
Clinical & Molecular DX
JUL 11, 2018
Certain tests better flag fetuses with brain disorder risk
Fetuses with a specific, rare chromosomal aberration have a 20 percent risk of developmental or other brain disorder, new research shows. The work could le...
Loading Comments...